AtaiBeckley
AtaiBeckley Inc.
- HQ
- United States
- Registry
- SEC EDGAR · CIK 2081043
- Status
- acquired
- Listing
- Private
- Current stage
- wholly owned subsidiary of Eli Lilly and Company since 2026-09-11; Form 15-12G filed 2026-09-21
- Key people
- All directors and executive officers resigned at the Effective Time 2026-09-11; directors now Christopher Anderson and Jonathan R. Haug; officers Jonathan R. Haug (President), Steffanie Lim-Ho (Treasurer), Christopher Anderson (Secretary), Jonathan Groff and Jamie Burnett (Assistant Secretaries), Katie Lodato (Assistant Treasurer). Retention bonus of $194,000 approved 2026-09-10 for COO Gerd Kochendoerfer
- Investors
- Eli Lilly and Company (100%). Apeiron Investment Group Ltd, Apeiron Presight Capital Fund II, Presight Capital Management I and Fabian Hansen report 0 shares on Schedule 13D/A No. 5, event date 2026-09-11
sec.govregistryverified 2026-11-02
Notes on the record
Formed from the atai / Beckley Psytech combination. IR address 250 West 34th Street, New York. Sponsor of record on ClinicalTrials.gov for VLS-01 is 'atai Therapeutics, Inc.' and for BPL-003 is 'Beckley Psytech Limited'; a sponsor search on 'AtaiBeckley' returns zero records. See D001-lilly-ataibeckley-2026. Supersedes the row verified 2026-08-25. Stockholder approval 2026-09-08 (8-K Item 5.07); merger closed 2026-09-11 (8-K Items 2.01, 3.01, 5.01, 5.02, 5.03); fifteen Form 4s filed 2026-09-11 report cancellation of insider options and RSUs for cash plus CVRs; POS AM and POSASR filed 2026-09-11 deregister unsold shares. RE-VERIFIED 2026-11-02. Changed: current_stage, source_url. EDGAR CIK 2081043 (HTTP 200): Form 15-12G 0001140361-26-037188 filed 2026-09-21, terminating registration of the common stock under Section 12(g), registrant address now Lilly Corporate Center, Indianapolis; S-8 POS filed 2026-09-16 (two) and 2026-09-17. No filing after 2026-09-21 as of 2026-11-02. Supersedes the row verified 2026-09-15 (kept), per DATA LAYER rule 4.
Assets
Phase 2b complete; company stated Phase 3 activities initiated (Q2 2026 10-Q); no Phase 3 record on ClinicalTrials.gov or CTIS as of 2026-11-02. Sweeps 2026-11-02: ClinicalTrials.gov query.intr BPL-003 returns 4 records, max Phase 2; mebufotenin 6, all GH Research, max Phase 2; VLS-01 1, Phase 2. CTIS search BPL-003 returns 1 record (2024-513457-70-00, Ended 2025-06-26). NCT05870540 COMPLETED, record last updated 2026-09-10 · treatment-resistant depression; separate Phase 2 in alcohol use disorder
clinicaltrials.govregistryverified 2026-11-02
Registered trials
PHASE1 · Pharmacokinetics in Healthy Adults · COMPLETED · United Kingdom
clinicaltrials.govctgov registryverified 2026-08-31
PHASE2 · Treatment Resistant Depression · RECRUITING · United Kingdom
clinicaltrials.govctgov registryverified 2026-08-31
PHASE2 · Alcohol Use Disorder · COMPLETED · United Kingdom
clinicaltrials.govctgov registryverified 2026-08-31
PHASE2 · Treatment Resistant Depression · COMPLETED · Australia, Germany, Poland, Spain, United Kingdom, United States
clinicaltrials.govctgov registryverified 2026-09-15
Therapeutic exploratory (Phase II) · Treatment-Resistant Depression (TRD) · Ended · Germany, Poland, Spain
euclinicaltrials.euctis registryverified 2026-08-31
PHASE1 · Pharmacokinetics in Healthy Adults · COMPLETED · United Kingdom
clinicaltrials.govctgov registryverified 2026-10-13inferred
Deals
Eli Lilly and Company acquires AtaiBeckley Inc.
acquisition · closed · $3800m headline
sec.govsec filingverified 2026-11-02
In the briefing
8 issues tagged ATAIBECKLEY.